ABSTRACT-YM060, (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-lH-benz imidazole hydrochloride, is a new serotonin (5HT)3-receptor antagonist. We examined the effects of YM060 on chemotherapeutic agent-, apomorphine and copper sulfate induced emesis. Intravenous YM060 potently prevented cisplatin (10 mg/kg, i.v.)-in duced emesis with ED50 values of 0.06 (0.05 -0.07) ,tg/kg, i.v. in ferrets. Based on the ED50 values, YM060 was 300, 20 and 100 times more potent than ondansetron, granisetron and the S-isomer of YM060, respectively. The relative potencies of these drugs described above were similar to those in the previously reported 5HT3-receptor antagonism. YM060 given orally also potently inhibited cisplatin (10 mg/kg, i.p.) and cyclophosphamide (200 mg/kg, i.p.)-induced emesis in ferrets with ED_,,() values of 0.1 (0.09-0.11) and 0.02 (0.16-0.27) ,ug/kg, p.o., respectively. All tested 5HT3-receptor antagonists including YM060 failed to prevent apomorphine (0.1 mg/kg, s.c.)-induced emesis in dogs and copper sulfate (1%, 10 ml, p.o.)-induced emesis in ferrets. Our data indicate that YM060 is a highly potent inhibitor of chemotherapeutic agent-in duced emesis and that the antiemetic effect of YM060 may be depend on 5HT3-recep tor antagonism.
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Emesis and nausea are severe side-effects of cancer chemotherapy. The dopamine D2-re ceptor antagonists domperidone and metoclo pramide used in conventional antiemetic thera py have only weak effects against chemothera peutic agent-induced vomiting. In 1985, metoclopramide was reported to antagonize the serotonin M receptor (1), which was re designated the serotonin (5HT)3-receptor in 1986 (2). Several recently developed selective 5HT3-receptor antagonists effectively inhibit chemotherapeutic agent-induced emesis in both animals (3, 4) and man (5, 6) . A good correlation between 5HT3-receptor antagonis tic potency and antiemetic efficacy has been obtained. Furthermore, in animals, depletion of 5HT by fenfluramine could also prevent this emesis (7, 8) . Therefore, 5HT may play an important role via the 5HT3-receptor in the chemotherapeutic agent-induced emetic re sponse.
YM060 has been shown to be a potent 5HT3-receptor antagonist in the von Bezold Jarisch reflex in rats (9) and in the isolated colonic strips in guinea pigs (10) , and to be highly selective for the 5HT3-receptor (10) . In this study, we examined the antiemetic profile of YM060 against chemotherapeutic agent-, apomorphine and copper sulfate-induced emesis in ferrets and dogs, and we compared the results with those for ondansetron, gra nisetron and metoclopramide. Since YM060 has an asymmetric center in its chemical struc ture (Fig. 1) , its enantiomer (S-form) exists. We therefore studied the stereoselectivity of this compound in its inhibition of cisplatin-in duced emesis in ferrets using its S-isomer and the racemate. 
MATERIALS AND METHODS

Animals
Experiments were performed on male fer rets weighing 1-1.5 kg obtained from Mar shall Farms (North Rose, NY) or beagle dogs of both sexes weighing 10 -14 kg. They were allowed free access to food and water before the experiment. Each animal was used for only one experiment. They were housed in in dividual cages for the observation of emesis.
Inhibitory effects of intravenous drugs on cisplatin-induced emesis in ferrets
To evaluate intravenously administered test drugs, ferrets were lightly anesthetized with diethylether, the instep of a foot was incised and the test drugs were injected through a su perficial dorsal metatarsal vein. After the inci sions were sutured, the ferrets were allowed to recover from the anesthesia. Thirty minutes after injection of test drugs, cisplatin was simi larly injected through a vein of the other foot. They were allowed to recover from anesthesia for a further 10 to 20 min. Emesis was re corded for 4 hr after injection of the cytotoxic drug. Emesis was defined as rhythmic abdom inal contractions, either with (vomiting) or without (retching) associated expulsion of solid or liquid material. The time to onset of vomiting and/or retching was recorded for each animal, as were the number of vomits and/or retches associated with each episode of emesis.
Inhibitory effects of oral drugs on cisplatin-in duced emesis in ferrets
To evaluate the antiemetic effects of test drugs dosed orally, emesis was induced by cis platin (10 mg/kg, i.p.) in ferrets. Test drugs were administered 1 hr prior to cisplatin, and the number of episodes and onset time of emesis were recorded for each animal as men tioned above for 4 hr after administration of cisplatin. For ferrets which did not vomit, the latency period was taken as 240 min (i.e., the observation period).
Inhibitory effects of oral drugs on cyclophos phamide-induced emesis in ferrets YM060, ondansetron, granisetron or meto clopramide was orally dosed 1 hr before cyclo phosphamide (200 mg/kg, i.p.). As with cis platin, ferrets were observed for 4 hr after the emetogenic agent.
Apomorphine-induced emesis in dogs
In preliminary studies, the response of fer rets to apomorphine at doses of 0.1 to 1 mg/kg, s.c. was not dose-dependent, and not all animals vomited even at the highest dose of 1 mg/kg. Even if those emetic responses were observed, they were weak (data not shown). These results were consistent with previous studies (7, 11) . On the other hand, all tested beagle dogs responded to apomor phine at 0.1 mg/kg, s.c. Beagle dogs, there fore, were used for the apomorphine-in duced emesis. YM060, ondansetron, gra nisetron, metoclopramide or saline was ad ministered subcutaneously 30 min before injec tion of apomorphine. Dogs were observed for a period of 1 hr after administration of apo morphine, and the number of emetic episodes was recorded.
Copper sulfate-induced emesis in ferrets YM060, ondansetron, granisetron, metoclo pramide and saline were subcutaneously dosed 30 min before intragastric copper sulfate (1%, 10 ml). Ferrets were observed for emesis for 1 hr after copper sulfate dosing.
Statistical analysis
Results are expressed as the mean ± S.E.M. Number of emetic episodes at each dose from different experiments were grouped, and a one-way analysis of variance was followed by the Mann-Whitney U-test. Probit analysis was used to obtain ED50 values and 95% confidence limits.
Drugs
YM060, its enantiomer (S-form) and race mate, granisetron HC1, ondansetron HCl and metoclopramide HC1 were prepared by Yama nouchi Pharmaceutical Co., Ltd. These drugs were suspended in 0.5% methylcellulose solu tion for oral administration or dissolved in saline solution for parenteral administration. Cisplatin was purchased from Bristol-Myers Squibb. Cyclophosphamide (Wako Junyaku), apomorphine (Sigma) and copper sulfate (Wako Junyaku) were dissolved in distilled water before use. All doses are expressed as the base.
RESULTS
Inhibitory effects of intravenous 5HT3-receptor antagonists on cisplatin-induced emesis in fer rets
Intravenously administered cisplatin (10 mg/kg) caused emesis with an average fre quency of about 14 times during the 4-hr observation period with the first episode occuring around 100 min (Table 1) . YM060, ondansetron and granisetron given in travenously effectively prevented this emesis ( Fig. 2 and Table 1 ), while metoclopramide required high doses to be effective. ED50 values for these compounds were 0.06 pg/kg for YM060, 21.0 pg/kg for ondansetron, 1.3 ,ug/kg for granisetron and 520 Mg/kg for metoclopramide. Therefore, inhibitory activity of YM060 was 300, 20 and 8700 times more potent than that of ondansetron, granisetron and metoclopramide, respectively. Emesis was completely blocked by YM060 at 0.3,ug/kg, ondansetron at 100 ,ug/kg and granisetron at 30,ug/kg. These drugs significantly delayed the first episode ( Table 1 ). The S-isomer and racemate of YM060 also inhibited emesis in a dose-dependent fashion, with ED50 values of 5.7 and 0.16,ug/kg; therefore, they were approximately 100 and 3 times less potent than YM060, respectively.
Inhibitory effects of oral 5HT3-receptor antago nists on cisplatin-induced emesis in ferrets
Intraperitoneal cisplatin (10 mg/kg) also re peatedly induced emetic responses with an average frequency of about 10 times during the 4-hr observation period in all control fer rets ( Table 2 ). The first episode occured around 100 min, similar to the intravenously treated animals described above. When admin istered orally, YM060, ondansetron, gra nisetron and metoclopramide inhibited the emetic response in a dose-dependent fashion (Table 2) , with ED50 values of 0.1, 49.9, 40.7 and 2056 ,u g/kg, respectively. By administra tion of high doses of these drugs: YM060 at 0.1 ug/kg and ondansetron and granisetron at 300 pg/kg, no emetic episode was observed during the 4-hr observation period. These drugs significantly increased the latency to the first emetic response ( Table 2 ). The S-isomer and the racemate of YM060 also dose-depend ently inhibited cisplatin-induced emesis. Judg ing from the ED50 values of 8.3,ug/kg for the S-form and 0.17 ug/kg for the racemate, the S-isomer and the racemate were approximate ly 80 and 2 times less potent than YM060, re spectively. Dosing studies in cisplatin-treated ferrets showed the effective dose-ranges of oral and intravenous YM060 to be almost equal (0.1-1 ,ug/kg).
Inhibitory effects of oral 5HT3-receptor antago nists on cyclophosphamide-induced emesis in ferrets
Cyclophosphamide at a dose of 200 mg/kg, i.p. caused multiple emetic responses over the 4-hr period, with all control ferrets responsive to the drug. All three 5HT3-receptor antago nists produced significant dose-dependent protection against this emesis (Table 3) . ED50 values were 0.02 Mg/kg for YM060, 139.9 ,ug/kg for ondansetron and 42.5,ug/kg for granisetron. When YM060 was administered at a dose of 1 u g/kg, p, o. , no emetic response was observed during the 4-hr observation period. As shown in Table 3 , these com pounds significantly increased the latency to the first episode of emesis. 
DISCUSSION
In the present study, intravenous YM060 and the other tested compounds inhibited cisplatin-induced emesis in a dose-dependent manner. YM060 was approximately 20, 310 and 8670 times more potent than granisetron, ondansetron and metoclopramide, respective ly. This potency ranking of YM060 > gra nisetron > ondansetron > metoclopramide was consistent with that for 5HT3-receptor antago nism obtained from the von Bezold-Jarisch reflex in rats (9) and isolated colonic contrac tion in guinea pigs (10) induced by 5HT and 2methyl-5HT. YM060 dosed orally prevented cisplatin-induced emesis in a dose range simi lar to that for intravenous administration. Based on the oral to intravenous ED50 ratio in the antiemetic effects on cisplatin-induced emesis, YM060 showed a pharmacological bioavailability (p.o./i.v. ratio) of 1.7, similar to that of ondansetron (2.7) and better than that of granisetron (31.3). These data support the idea that YM060 is a highly potent and orally active 5HT3-receptor antagonist.
In addition to cisplatin, we used cyclophos phamide as another chemo-therapeutic agent to induce emesis in ferrets. The three 5HT3 receptor antagonists dose-dependently pre vented this emesis and delayed its onset. In hibitory effects of YM060 were much more potent than those of the other two drugs, and the potency ranking was the same as in cisplatin-induced emesis. Cyclophosphamide induced the first episode of emesis within approximately 20 min, much sooner than that by cisplatin. It has been reported that ablation of area postrema abolishes cisplatin's emetic effects, but not those of cyclophosphamide (12) . Thus, the mechanism of action may not be identical to that of cisplatin. On the other hand, abdominal visceral nerve lesions can abolish both cisplatin and cyclophospha mide-induced emesis (12) , and in our study, 5HT3-receptor antagonists prevented cyclo phosphamide-induced emesis with a potency ranking similar to that in cisplatin-induced emesis. We therefore suggest that there is some common pathway in cisplatin and cyclophosphamide-induced emetic responses and that the 5HT3-receptor may be involved in this pathway. Due to its asymmetric center, its enantiomer can exist. Both YM060 (R-form) and its S form dose-dependently prevented cisplatin-in duced emesis. Based on the ED50 values, in travenous and oral dosing produced potency ratios of YM060 over the S-form of 95 and 83, respectively. This ratio was similar to those obtained in the 5HT-induced von Bezold Jarisch reflex in rats (S/R ratio of 222) (9) and in guinea pig colonic contraction (S/R ratio of 173) (10) . These results suggest that 5HT3-receptors recognize the comformational difference between YM060 and its S-form, and favor the R-form over the latter. Stereo selectivity was also reported for ondansetron (13) and zacopride (14) . In the case of ondan setron, there is an asymmetric center at the corresponding position to YM60, and a similar relation of potencies exists between the R and S-form as YM060 and its S-form. Howev er, YM060's stereo-selectivity over its S-form was approximately 10 times greater than those for ondansetron over its S-form and for zecop ride over its R-form. Therefore, YM060 and its enantiomer may be useful pharmacological tools for investigating the interaction of 5HT3 receptors and ligands.
Some reports suggest the heterogeneity of 5HT3-receptors (15, 16) . However, the present and other studies (9, 10) examining the poten cy ratios of YM060, its S-form and racemate, ondansetron and granisetron showed no evi dence of heterogeneity in the 5HT3-receptors involved in the chemotherapeutic agent-in duced emetic response in ferrets, 5HT-induced von Bezold-Jarisch reflex in rats, and 5HT-in duced contraction of isolated guinea pig colon. In the chemotherapeutic agent-induced emetic response, therefore, YM060 may block the same type of receptor as those involved in the von Bezold-Jarisch reflex and colonic contrac tion induced by 5HT. However, we used several compounds only, and the present and other two studies on YM060 (9, 10) each used different animals. Therefore, further investiga tion will be needed to determine whether 5HT3-receptor subtypes exist or not.
We used apomorphine and copper sulfate as non-chemotherapeutic emetics. Apomorphine induced emesis by stimulating dopamine re ceptors in the area postrema (17) . Metoclopra mide with known anti-dopaminergic activity, almost completely antagonized apomorphine induced emesis at a dose of 0.1 mg/kg, s.c. However, no tested 5HT3-receptor antagonist prevented this emesis at doses that completely blocked chemotherapeutic agent-induced eme sis. These results agreed with those in binding studies using rat striatum preparation, in which YM060 was shown to be selective for 5HT3-receptors, with no detectable affinity to dopamine D2-receptors at up to 105 M (18) . Copper sulfate given intragastrically causes gastrointestinal irritation and initiates the vomiting reflex. The 5HT3-receptor antagonist ICS205-930 was unable to inhibit this emesis (1) . All three 5HT3-receptor antagonists tested in the present study failed to suppress this copper sulfate-induced emesis at doses that prevented chemotherapeutic agent-induced emesis. These results indicate that 5HT3-re ceptors may not be involved in the emetic re sponses induced by apomorphine and copper sulfate. Our finding that 5HT3-receptor antago nists selectively blocked chemotherapeutic agent-induced emesis in ferrets was consistent with a previous report using this animal (1). Similar antiemetic profile for 5HT3-receptor antagonists were reported in dogs (19) , cats (20) and Suncus murinus which was recently reported as an animal suitable for research on antiemetic drugs (21) .
In summary, YM060 by intravenous and oral administration proved to be a highly effective inhibitor of chemotherapeutic agent induced emesis, and this effect may depend on 5HT3-receptor antagonism.
